CTRI/2024/02/062550招募中Unknown
A Randomized, Open Label, Multicenter, Multiple Dose, Two Treatment, Two Period, Two Way, Crossover, Steady State Bioequivalence Study Between Paliperidone Palmitate Extended Release Intramuscular Injectable Suspension 156 mg per mL of Eugia Pharma Specialities Limited, India and INVEGA SUSTENNA Paliperidone Palmitate Extended Release Intramuscular Injectable Suspension 156 mg per mL Manufactured for Janssen Pharmaceuticals, Inc Titusville, NJ 08560, USA in Adult Patients with Schizophrenia or Schizoaffective Disorder. - NI
试验速览
- 阶段
- Unknown
- 状态
- 招募中
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Male or non-pregnant, non-lactating females aged 18-65 years (both inclusive) having a documented clinical diagnosis of schizophrenia or schizoaffective disorder according to the PI evaluation and
- •Diagnostic and Statistical (DSM-V).
- •2. Participant is willing to participate for the entire study and adhere to the study protocol and committed
- •for required clinic visits and dosing.
- •3. Written informed consent for participation in the study by the participant and participant’s legally acceptable representative (LAR) and willing to adhere to protocol requirements.
- •4. Participants having BMI between less the or equal to 18.00 - 30.00 kg per m2 (Both inclusive) and at least 50 kg weight for male participants and 48 kg for female participants.
- •5. Participants who at screening are on stable regimen of oral Paliperidone or Risperidone therapy or who are already receiving Paliperidone palmitate 156 mg per mL (100 mg Paliperidone) extended-release intramuscular injectable suspension and who at randomization are receiving a stable regimen of 156 mg per mL (100 mg Paliperidone) of monthly paliperidone palmitate extended-release suspension (at least 3 doses) via the intramuscular route.
- •6. Participants who are clinically stable and not hospitalized for exacerbation of psychiatric symptoms for at least 3 months before randomization.
- •7. Participants having treatment response score of less than 4 (unchanged or worse and side-effects outweigh the therapeutic effects) as evaluated using Clinical Global Impression scale by investigator at both screening and Baseline visits.
- •8. Participants not having any significant diseases or clinically significant abnormal findings except schizophrenia or schizoaffective disorder during screening.
- •9. Adequate organ and bone marrow function at screening and randomization.
排除标准
- •1. Participants with known hypersensitivity and or intolerance to study drug or any other component of the
- •drug or intolerance to oral paliperidone or risperidone prior to screening.
- •2. Pregnant or participants with childbearing potential not practicing contraceptive or other barriers of contraception.
- •3. Participants with a history of Neuroleptic Malignant Syndrome (NMS) while on treatment with antipsychotics.
- •4. History or presence of clinically significant cardiovascular disease, especially known history of QT prolongation, congenital long QT syndrome, recent acute myocardial infarction, cardiac arrythmias or uncompensated heart failure.
- •5. Participants with the QT prolongation risk. QTC more than 450 ms in male, QTC more than 470 ms in female .
- •6. Participants with current or relevant history of psychiatric illness except schizophrenia.
- •7. Participants with clinically significant illnesses or participant that have had major surgery within 4 weeks prior to first dosing of IMP and stabilization (if applicable), or who have not recovered from prior major surgery.
- •8. Participants with concurrent condition of Parkinson disease (except for drug-induced extrapyramidal
- •syndrome). Participants with history or presence of tardive dyskinesia. Participants with cognitive and
- •motor impairment.
- •9. Participants with concomitant treatment with hepatic enzyme inhibitors (including fluoxetine or
- •paroxetine) or medications known to interact with study medication or stabilization dose (if applicable)
- •within 2 weeks of the first dose.
- •10. Treatment with any of the following therapies:
- •Injection of risperidone long-acting injection within 6 weeks before randomization.
- •Electroconvulsive therapy within 3 months prior to screening.
- •Clozapine within 3 months before screening
- •11. Presence of syncope or orthostatic hypotension (defined as systolic blood pressure decrease of at least 30 mmHg or a diastolic blood pressure decrease of at least 20 mmHg within one to three minutes of standing up).
- •12. Participants with uncontrolled hypertension (systolic BP more than 150 mmHg diastolic BP more than 100 mmHg).
研究者
相似试验
招募中
Unknown
Two-treatment Bioequivalence Study of Paliperidone Palmitate in adult schizophrenic patientsCTRI/2023/06/054479American Regent, Inc.
尚未招募
Unknown
Study to evaluate the bioequivalence and safety of Etonogestrel Implant in Healthy Female ParticipantsCTRI/2024/08/072277oop Therapeutics LLC
尚未招募
不适用
This is a study to compare two formulations of Felbamate in Eplileptic patientsCTRI/2018/07/014839Glasshouse Pharmaceuticals Limited Canada
已完成
1 期
Pharmacokinetic study of two formulations of paliperidone palmitate extended-release injectable suspension in patients with schizophrenia.CTRI/2018/05/013703Mylan Laboratories Limited267
招募中
4 期
A multicenter, open-label, non-inferiority, randomized controlled trial comparing mechanochemical endovenous ablation using Flebogrif with endovenous laser ablation in the treatment of primary great saphenous vein incompetenceNL-OMON25145oordwest Ziekenhuisgroep320